MIVetsCan: Cannabidiol (CBD)-Care Trial

Introduction and clinical context

The study MIVetsCan: Cannabidiol (CBD)-Care Trial (ClinicalTrials.gov · em andamento) is part of the scientific research on the use of cannabinoids in pain and neuropathy.

Chronic pain — especially neuropathic pain, caused by injury or dysfunction of the nervous system — is one of the most studied indications of medical cannabis. Cannabinoids such as THC and cannabidiol (CBD) act on the endocannabinoid system, which takes part in the modulation of pain and inflammation. The evidence points to a more consistent analgesic effect precisely in neuropathic pain, although the magnitude of the benefit varies across studies and populations. Cannabis is also investigated as a strategy to reduce opioid use in non-cancer chronic pain, always under medical supervision.

Understanding what science shows about the use of cannabinoids in pain and neuropathy helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This study is registered on ClinicalTrials.gov and is ongoing. Clinical trial on the use of cannabidiol (CBD) in chronic pain management. As it is ongoing, there are no final published results yet. Following ongoing studies is important to anticipate the next evidence on the topic.

Mechanism of action and safety

Cannabinoids exert an analgesic effect by modulating the endocannabinoid system in the pathways of pain transmission and processing: THC acts on CB1 receptors and CBD on targets such as serotonergic receptors and TRPV1 channels. In terms of safety, the most common adverse effects are dizziness, drowsiness and dry mouth, and THC can cause dose-dependent psychoactive effects. It is important to watch for interactions with central nervous system depressants and, with prolonged use, the risk of tolerance. Gradual titration and medical follow-up reduce risks, especially in those already using opioids or other analgesics.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (ClinicalTrials.gov · em andamento). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis work for chronic pain?

The evidence is more consistent for neuropathic pain; use should be individualized and prescribed by a doctor.

Does cannabis help reduce opioids?

Some studies suggest that, as an adjuvant, it can help reduce the opioid dose in non-cancer chronic pain.